Back grey_arrow_rt.gif
Norvir Access Updates: Co-Pay card, PAP, Welvista - see attached pdf
  Download the PDF here
Dear Community Friend:
Last year was economically difficult for so many people, and 2011 promises to bring more financial challenges. In response to even greater need, Abbott is increasing access to our HIV medications, Kaletra® (lopinavir/ritonavir) and Norvir® (ritonavir). Working with community leaders in the United States, Abbott is making some important changes and expanding several existing programs.
· The Norvir co-pay card will begin paying private insurance co-pays at the first dollar up to $50.00. The previous co-pay card paid from $25.00 through $50.00. Abbott will continue to provide the Kaletra Co-Pay Plus card, which covers up to $50.00 of co-pay costs for Kaletra and up to $50.00 each for two additional HIV medications in the Kaletra regimen. Both co-pay cards are available in physician offices.
· Abbott has increased donations to the Abbott Patient Assistance Foundation, to expand eligibility for uninsured patients prescribed Kaletra from 400% of Federal Poverty Level (FPL) to 500% of FPL. This will match or exceed all state AIDS Drugs Assistance Program (ADAP) qualifications and will allow the Foundation to help even more patients. More information about the Abbott Patient Assistance Foundation may be found at or by calling 1-800-222-6885.
· Abbott is also extending our support of Welvista and the Heinz Family Philanthropies to enable more patients on State ADAP waiting lists to get their medications quickly and easily with one application. Please visit or call 1-877-258-1556 for additional information.
Abbott is committed to expanding access to Kaletra and Norvir for those living with HIV. As we move through 2011, we will continue to communicate with community leaders to monitor the success of these programs and will look forward to your feedback.
Thank you for all of the hard work you do for patients in the HIV community.
Pdf attached
  icon paper stack View Older Articles   Back to Top